Harrow reported first-half 2026 revenue of around $115 million, below expectations due to VEVYE pricing changes. The company maintained full-year guidance of $350 million to $365 million, requiring $235 million to $250 million in second-half revenue. IHEEZO delivered record quarterly demand of 65,477 units despite losing pass-through reimbursement, whilst ordering accounts grew 32% year-over-year. VEVYE prescriptions increased 21% sequentially, outpacing the 14% broader market growth, with market share rising to 14.6%. TRIESENCE demand surged 162% year-over-year to 14,529 units. However, adjusted EBITDA remained negative at $1.2 million. The pending TYRVAYA acquisition adds $20 million in annual costs. Hedge fund ownership declined from 24 to 22 funds, whilst short interest stands at 20.14% of float.

Harrow reported second-quarter revenue of $70.7 million, up 11% year-over-year, driven by stronger demand for VEVYE, IHEEZO and specialty products. The ophthalmic pharmaceutical company reiterated full-year revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million. VEVYE generated $29.4 million in quarterly revenue, up nearly 58% year-over-year, whilst IHEEZO contributed $15.6 million. Management expects second-half growth from improved VEVYE pricing, IHEEZO's 25% net price increase, and the BYOOVIZ and VERKAZIA launches. Harrow plans to acquire global rights to TYRVAYA for $30 million in cash, expecting more than $30 million of revenue in 2027 if the deal closes. The company also advanced pipeline programmes G-MELT and YOCHIL, targeting FDA submissions in 2027.

Harrow has announced the commercial launch of BYOOVIZ (ranibizumab-nuna) in the United States, an FDA-approved biosimilar referencing LUCENTIS. The launch follows Harrow's exclusive US commercialisation agreement with Samsung Bioepis, which also includes rights to OPUVIZ (aflibercept-yszy), another ophthalmology biosimilar. BYOOVIZ is approved for treating Neovascular Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, and Myopic Choroidal Neovascularization. It was designated by the FDA as the first interchangeable ophthalmology biosimilar in the US. The product joins Harrow's expanding retina franchise, which includes IHEEZO and TRIESENCE. The company aims to strengthen its position in the estimated $9 billion US anti-VEGF market, providing retina specialists with buy-and-bill products for treating sight-threatening retinal diseases.